SCHEMBL6832377

SCHEMBL6832377

CCOc1cc(F)cc(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
FGFR1 P11362 1/20 0.41
FGFR2 P21802 1/20 0.41
NQO1 P15559 1/20 0.41
EPAS1 Q99814 11/20 0.38
KAT6A Q92794 1/20 0.35
VEGFA P15692 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1547677 0.84 MAPT (0.54) MAPTNQO1
SCHEMBL3780893 0.84 NQO1 (0.50) MAPTNQO1
SCHEMBL1680217 0.84 NQO1 (0.50) MAPTFGFR1FGFR2NQO1KAT6A
SCHEMBL5671801 0.84 NQO1 (0.50) FGFR1FGFR2NQO1KAT6A
SCHEMBL12093390 0.77 ESR1 (0.50) MAPTFGFR1FGFR2NQO1KAT6A
SCHEMBL256791 0.77 NQO1 (0.42) MAPTFGFR1FGFR2NQO1KAT6A
SCHEMBL16956758 0.77 MAPT (0.42) MAPTNQO1KAT6A
SCHEMBL27870127 0.76 MAPT (0.43) MAPTEPAS1VEGFA
SCHEMBL12497629 0.76 MAPT (0.43) MAPTEPAS1VEGFA
SCHEMBL31405023 0.76 ALDH1A1 (0.46) EPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377434-B2 Methods for preparing substituted chromanone derivatives HANGZHOU DUYI TECHNOLOGY CO. LTD. (CN) 2022-07-05 US disclosed
US-20220024890-A1 METHODS FOR PREPARING SUBSTITUTED CHROMANONE DERIVATIVES HANGZHOU DUYI TECHNOLOGY CO. LTD. (CN) 2022-01-27 US disclosed
WO-2017117406-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. (US) 2017-07-06 WO disclosed
US-8183238-B2 Bicyclic and tricyclic compounds as KAT II inhibitors PFIZER INC. (US) 2012-05-22 US disclosed
US-20100324043-A1 Bicyclic And Tricyclic Compounds As KAT II Inhibitors PFIZER INC 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324043-A1 Bicyclic And Tricyclic Compounds As KAT II Inhibitors KAT2A, KAT2B, KAT6B MAPT 258/4885FGFR1 4561/4885FGFR2 4421/4885
US-20220024890-A1 METHODS FOR PREPARING SUBSTITUTED CHROMANONE DERIVATIVES CBR3, CYP2F1, CBR1 MAPT 4832/4885FGFR1 3592/4885FGFR2 4001/4885
US-11377434-B2 Methods for preparing substituted chromanone derivatives CYP2E1, CYP2F1, CBR1 MAPT 4832/4885FGFR1 3465/4885FGFR2 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.